Dauwe Pharma Consultancy: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Dauwe Pharma Consultancy
Largest movements
- Cash -€78,187
down €78,187 (-48.9%), from €159,952 to €81,765
mainly Tax, wage and social debts (-€70,665) and Receivables within one year (-€6,479)
- Receivables within one year +€6,479
up €6,479 (+8.4%), from €76,816 to €83,295
of which Other amounts receivable: +€6,479
- Tax, wage and social debts -€70,665
down €70,665 (-99.8%), from €70,811 to €146
- Gross operating margin -€229
down €229 (-5.8%), from -€3,915 to -€4,144
- Financial income -€161
down €161 (-3.4%), from €4,683 to €4,522
- Taxes -€103
down €103 (-82.8%), from €125 to €21
- Other operating charges +€75
up €75 (+100%), from €75 to €150
- Financial charges +€58
up €58 (+83.7%), from €69 to €128
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €241,451 | €169,582 | -€71,869 | -29.8% |
| Current assets | 29/58 | €241,451 | €169,582 | -€71,869 | -29.8% |
| Amounts receivable within one year | 40/41 | €76,816 | €83,295 | +€6,479 | +8.4% |
| Trade receivables | 40 | €0 | - | = | |
| Other amounts receivable | 41 | €76,816 | €83,295 | +€6,479 | +8.4% |
| Cash at bank and in hand | 54/58 | €159,952 | €81,765 | -€78,187 | -48.9% |
| Deferred charges and accrued income | 490/1 | €4,683 | €4,522 | -€161 | -3.4% |
| Total equity and liabilities | 10/49 | €241,451 | €169,582 | -€71,869 | -29.8% |
| Equity | 10/15 | €169,278 | €169,357 | +€79 | 0.0% |
| Contributions | 10/11 | €2,000 | €2,000 | = | 0.0% |
| Reserves | 13 | €160,000 | €160,000 | = | 0.0% |
| Distributable reserves | 133 | €160,000 | €160,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | €7,278 | €7,357 | +€79 | +1.1% |
| Amounts payable | 17/49 | €72,173 | €225 | -€71,948 | -99.7% |
| Amounts payable within one year | 42/48 | €72,173 | €225 | -€71,948 | -99.7% |
| Trade debts | 44 | €1,362 | €79 | -€1,283 | -94.2% |
| Suppliers | 440/4 | €1,362 | €79 | -€1,283 | -94.2% |
| Taxes, remuneration and social security | 45 | €70,811 | €146 | -€70,665 | -99.8% |
| Taxes | 450/3 | €70,811 | €146 | -€70,665 | -99.8% |
| Other operating charges | 640/8 | €75 | €150 | +€75 | +100% |
| Gross operating margin | 9900 | -€3,915 | -€4,144 | -€229 | -5.8% |
| Operating profit (loss) | 9901 | -€3,990 | -€4,294 | -€304 | -7.6% |
| Financial income | 75/76B | €4,683 | €4,522 | -€161 | -3.4% |
| Recurring financial income | 75 | €4,683 | €4,522 | -€161 | -3.4% |
| Financial charges | 65/66B | €69 | €128 | +€58 | +83.7% |
| Recurring financial charges | 65 | €69 | €128 | +€58 | +83.7% |
| Profit (loss) for the period before taxes | 9903 | €623 | €101 | -€523 | -83.9% |
| Income taxes | 67/77 | €125 | €21 | -€103 | -82.8% |
| Profit (loss) for the period | 9904 | €499 | €79 | -€419 | -84.1% |
| Profit (loss) for the period to be appropriated | 9905 | €499 | €79 | -€419 | -84.1% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 17 October 2026 via checked.be.